Wilson Disease Clinical Trial
Official title:
A Phase 2, Open-label Study to Assess Copper and Molybdenum Balance in Participants With Wilson Disease Treated With ALXN1840
Verified date | October 2023 |
Source | Alexion Pharmaceuticals, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This exploratory study will investigate the effects of ALXN1840 on copper balance in participants with Wilson disease (WD).
Status | Completed |
Enrollment | 9 |
Est. completion date | September 1, 2022 |
Est. primary completion date | August 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Diagnosis of WD by Leipzig Criteria = 4. 2. Able to reside in the clinical research unit for intensive metabolic monitoring of copper and molybdenum. 3. Participants willing to adhere to copper/molybdenum-controlled diet during the study. 4. Willing and able to follow protocol-specified contraception requirements. 5. Capable of giving signed informed consent. Exclusion Criteria: 1. Decompensated cirrhosis or model for end stage liver disease score > 13. 2. Modified Nazer score > 7. 3. Clinically significant gastrointestinal bleed within past 3 months. 4. Alanine aminotransferase > 2 × upper limit of normal. 5. Hemoglobin less than lower limit of the reference range for age and sex. 6. Significant medical history (current or past). 7. Previous treatment with zinc within 30 days prior to the Screening Visit. 8. Participants in renal failure, defined as in end-stage renal disease on dialysis (chronic kidney disease stage 5) or creatinine clearance < 30 milliliters/minute. |
Country | Name | City | State |
---|---|---|---|
New Zealand | Clinical Study Site | Grafton | Auckland |
United Kingdom | Clinical Study Site | London | |
United States | Clinical Study Site | Lincoln | Nebraska |
United States | Clinical Study Site | New Haven | Connecticut |
Lead Sponsor | Collaborator |
---|---|
Alexion Pharmaceuticals, Inc. |
United States, New Zealand, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Mean Daily Copper Balance: Day 1 Through Day 8 | Copper balance is defined as the difference between the measured copper input in food and drink, and the measured copper elimination in urine and feces, and was calculated as the average daily copper balance over the collection period. | Accumulation: Day 1 through Day 8 (ALXN1840 15 mg) | |
Primary | Mean Daily Copper Balance: Day 31 Through Day 35 | Copper balance is defined as the difference between the measured copper input in food and drink, and the measured copper elimination in urine and feces, and was calculated as the average daily copper balance over the collection period. | Accumulation: Day 31 through Day 35 (ALXN1840 30 mg) | |
Primary | Mean Daily Copper Balance: Day 25 Through Day 28 | Copper balance is defined as the difference between the measured copper input in food and drink, and the measured copper elimination in urine and feces, and was calculated as the average daily copper balance over the collection period. | Accumulation: Day 25 through Day 28 (ALXN1840 15 mg) | |
Primary | Mean Daily Copper Balance: Day 36 Through Day 39 | Copper balance is defined as the difference between the measured copper input in food and drink, and the measured copper elimination in urine and feces, and was calculated as the average daily copper balance over the collection period. | Accumulation: Day 36 through Day 39 (ALXN1840 30 mg) | |
Secondary | Change From Baseline In Mean Daily Copper Balance | Copper balance is defined as the difference between the measured copper input in food and drink, and the measured copper elimination in urine and feces, and was calculated as the average daily copper balance over the collection period. | Accumulation: Baseline, Day 1 through Day 8 (ALXN1840 15 mg) and Day 31 through Day 35 (ALXN1840 30 mg); Steady State: Baseline, Day 25 through Day 28 (ALXN1840 15 mg) and Day 36 through Day 39 (ALXN1840 30 mg) | |
Secondary | Copper Quantified In Food, Drink, Feces, And Urine, Including Plasma Total And Labile Bound Copper (LBC) | Copper was assessed through measurement of copper intake (in food and drink), and copper output (in feces and urine) as well as plasma total and labile bound copper. | Accumulation: Day 1 through Day 8 for 15 mg and Day 31 through Day 35 for 30 mg; Steady state: Day 25 through Day 28 for ALXN1840 15 mg and Day 36 through Day 39 for ALXN1840 30 mg | |
Secondary | Molybdenum Specified In ALXN1840 Doses Given And Quantified In Food, Drink, Feces, And Urine, Including Plasma At Steady State | The amount of molybdenum in food, drink, feces and urine is reported in this outcome measure. | Day 25 through Day 28 (ALXN1840 15 mg) and Day 36 through Day 39 (ALXN1840 30 mg) | |
Secondary | Change From Baseline In Total Molybdenum Excretion In Urine And Feces | Accumulation: Baseline, Day 1 through Day 8 (ALXN1840 15 mg) and Day 31 through Day 35 (ALXN1840 30 mg); Steady State: Baseline, Day 25 through Day 28 (ALXN1840 15 mg) and Day 36 through Day 39 (ALXN1840 30 mg) | ||
Secondary | Mean Daily Molybdenum Balance At ALXN1840 Steady State | Molybdenum balance at steady state was assessed through measurement of molybdenum intake (in food, drink, and ALXN1840), and molybdenum output (in feces and urine). Steady state is defined as molybdenum (out) equal to molybdenum (in). | Steady state: Day 25 through Day 28 (ALXN1840 15 mg) and Day 36 through Day 39 (ALXN1840 30 mg) | |
Secondary | Accumulation Of Molybdenum As Determined By Molybdenum Balance | Molybdenum balance was assessed through measurement of molybdenum intake (in food, drink, and ALXN1840), and molybdenum output (in feces and urine). | Accumulation: Day 1 through Day 8 (ALXN1840 15 mg) and Day 31 through Day 35 ((ALXN1840 30 mg) | |
Secondary | Maximum Observed Plasma Concentration (Cmax) of Total Molybdenum and Plasma Ultrafiltrate (PUF) Molybdenum | Day 1 up to Day 39 | ||
Secondary | Area Under The Concentration Time Curve (AUC0-inf) of Total Molybdenum and Plasma Ultrafiltrate (PUF) Molybdenum | Day 39 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03539952 -
Trientine Tetrahydrochloride (TETA 4HCL) for the Treatment of Wilson's Disease
|
Phase 3 | |
Active, not recruiting |
NCT04884815 -
Study of UX701 Gene Transfer for the Treatment of Wilson Disease
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03659331 -
A Controlled Study of Potential Therapeutic Effect of Oral Zinc in Manifesting Carriers of Wilson Disease
|
N/A | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Completed |
NCT04965571 -
Clinical Features and Outcome of Wilson's Disease With Generalized Epilepsy in Chinese Patients
|
||
Terminated |
NCT05047523 -
Study of ALXN1840 Versus Standard of Care in Pediatric Participants With Wilson Disease
|
Phase 3 | |
Completed |
NCT04526210 -
Study of ALXN1840 on the Metabolism of a CYP2B6 Substrate in Healthy Participants
|
Phase 1 | |
Completed |
NCT00004338 -
Study of Zinc for Wilson Disease
|
Phase 4 | |
Enrolling by invitation |
NCT03655223 -
Early Check: Expanded Screening in Newborns
|
||
Completed |
NCT02273596 -
Efficacy and Safety Study of WTX101 (ALXN1840) in Adult Wilson Disease Patients
|
Phase 2 | |
Completed |
NCT02763215 -
The Assessment of Copper Parameters in Wilson Disease Participants on Standard of Care Treatment
|
||
Recruiting |
NCT05444127 -
Oral Health and Wilson's Disease: SOMAWI
|
||
Completed |
NCT04408300 -
Study of Retinal Vascular Parameters in Patients With Wilson's Disease
|
N/A | |
Active, not recruiting |
NCT05783687 -
Real World Evidence Study in Subjects With Wilson's Disease
|
||
Terminated |
NCT04909346 -
Adeno-Associated Virus (AAV) Antibody Study in Subjects OTC Deficiency, GSDIa, and Wilson Disease
|
||
Completed |
NCT03867526 -
Establishment of Human Cellular Disease Models for Wilson Disease
|
||
Enrolling by invitation |
NCT03589820 -
Plasma Exchange and Continuous Hemodiafiltration in Treatment of Wilson's Disease-related Liver Failure
|
N/A | |
Completed |
NCT04526197 -
Phase 1 Study of ALXN1840 on the Metabolism of a CYP2C9 Substrate in Healthy Participants.
|
Phase 1 | |
Not yet recruiting |
NCT06430359 -
Circadian Variation of Urinary Copper Excretion in Wilson Disease Patients
|
||
Completed |
NCT04910581 -
rTMS in Wilson Disease Dysarthria
|
N/A |